Abstracts tagged "Patient reported outcomes"

Abstract Number: 1907 • ACR Convergence 2023
Selection of a Candidate Instrument to Assess Flare in Osteoarthritis with Content Matching with Endorsed Domains
Fabiana Queiroga¹, Marita Cross², Lara Maxwell³, Leigh Callahan⁴, sam michel Cembalo⁵, Thomas Buttel², Cindy Copenhaver⁶, Jonathan Epstein⁷, david Hunter⁸, Lauren King⁹, Lyn March² and Francis Guillemin¹⁰, ¹Université de Lorraine, Antibes, France, ²University of Sydney, Sydney, Australia, ³OMERACT, Ottawa, ON, Canada, ⁴The University of North Carolina, Chapel Hill, NC, ⁵OMERACT, Nancy, France, ⁶OMERACT, Chapel Hill, NC, ⁷Université de Lorraine, Nancy, France, ⁸Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, ⁹Clinical Associate, Division of Rheumatology, St. Michael’s Hospital, Toronto, ON, Canada, ¹⁰Université de Lorraine, EA 4360 Apemac, Nancy, France
Background/Purpose: The Outcome Measures in Rheumatology group (OMERACT) developed methodological steps to select instrument(s) to assess content appropriateness of outcomes, as well as tools to…
Abstract Number: 2099 • ACR Convergence 2023
Lesser Impact of Lower-Small Joint Involvement on Pain Than Upper-Small Joint in Rheumatoid Arthritis: Analysis Based on a Large Rheumatoid Arthritis Database in Japan
Tetsuji Sawada¹, Susumu Nishiyama², Shigemoto Igari¹, Toshihiro Matsui³ and Shigeto Tohma⁴, ¹Tokyo Medical University Hospital, Shinjuku Tokyo, Japan, ²Kurashiki Medical Center, Kurashiki, Japan, ³NHO Sagamihara National Hospital, Kanagawa, Japan, ⁴NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: Previous studies have highlighted the influence of pain, functional impairment, and affected joint distribution on the discordance in the global assessment of disease activity…
Abstract Number: 2253 • ACR Convergence 2023
Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast
Joseph Merola¹, Philip J. Mease², April W. Armstrong³, Vibeke Strand⁴, Thomas Lehman⁵, Jiyoon Choi⁶, Brandon Becker⁶, Yichen Zhong⁷, Matthew J. Colombo⁷, Diamant Thaçi⁸, Androniki Bili⁷ and Alice B. Gottlieb⁹, ¹Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Keck School of Medicine of University of Southern California, Los Angeles, CA, ⁴Stanford University, Portola Valley, CA, ⁵Bristol Myers Squibb, Philadelphia, PA, ⁶Bristol Myers Squibb, Lawrenceville, NJ, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁹Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: As 41% of patients with psoriasis may be undiagnosed for psoriatic arthritis, treatments must relieve both dermatologic and musculoskeletal symptoms. Deucravacitinib (DEUC), an oral,…
Abstract Number: 026 • 2023 Pediatric Rheumatology Symposium
Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument in a Juvenile Systemic Sclerosis Cohort
Sophie Stefancic, Amanda Robinson, Haley Havrilla, Samantha Branton, Vibha Sood and Kathryn Torok, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gastrointestinal (GI) manifestations in juvenile onset systemic sclerosis (jSSc) reflect adult disease with a range of involvement along the GI tract, including oropharyngeal dysphagia…
Abstract Number: 042 • 2023 Pediatric Rheumatology Symposium
Prevalence of Chronic Pain in Childhood-onset Systemic Lupus Erythematosus and Juvenile Dermatomyositis
Sara Patrizi¹, Susmita Kashikar-Zuck², CARRA Registry Investigators³, Mekibib Altaye⁴ and Jennifer Weiss⁵, ¹Stanford Medicine, Children's Health, Palo Alto, CA, ²University of Cincinnati College of Medicine; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³CARRA, Washington, DC, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Pediatric Rheumatology, Hackensack Meridian School of Medicine, Hackensack University Medical Center, Hackensack, New Jersey, Hackensack, NJ
Background/Purpose: The prevalence, severity and impact of chronic pain in pediatric patients with autoimmune diseases such as childhood onset SLE (cSLE) and juvenile dermatomyositis (JDM)…
Abstract Number: 045 • 2023 Pediatric Rheumatology Symposium
Patient Reported Outcomes in Pediatric Vasculitis
Clare Peckenpaugh¹, Aimee Hersh², CJ Inman¹, Sara Stern¹, Erin Treemarcki², Peter Merkel³ and Karen James¹, ¹University of Utah Department of Pediatrics, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Pennsylvania, Philidelphia, PA
Background/Purpose: Vasculitis is a group of multisystem, often relapsing diseases that can affect patients through disease activity, damage, and treatment toxicity. Vasculitis in adults often…
Abstract Number: 058 • 2023 Pediatric Rheumatology Symposium
High Levels of Psychological Distress, Depression, and Anxiety Symptoms in Children with Pediatric Rheumatologic Diseases
Natalie Rosenwasser¹, Tamar Rubinstein², Andrea Knight³, Natoshia Cunningham⁴, Aimee Hersh⁵, Vincent Del Gaizo⁶ and Erin Treemarcki⁵, ¹Seattle Children's Hospital, seattle, WA, ²Children's Hospital at Montefiore, New York, NY, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Michigan State University, Grand Rapids, MI, ⁵University of Utah, Salt Lake City, UT, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ
Background/Purpose: Mental health problems are common in children with pediatric rheumatologic diseases (PRDs) and are associated with worsened quality of life and poorer disease-related outcomes.…
Abstract Number: 064 • 2023 Pediatric Rheumatology Symposium
Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis
Silvia Rosina¹, Ana Isabel Rebollo-Giménez², Letizia Tarantola³, Roberta Naddei⁴, Alessandro Consolaro², Angela Pistorio⁵ and Angelo Ravelli⁶, ¹IRCCS Istituto Giannina Gaslini, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, ³Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genova, Italy, ⁴Università degli Studi di Napoli Federico II, Dipartimento di Scienze Mediche Traslazionali, Napoli, Italy, ⁵IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, ⁶IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy
Background/Purpose: Increasing attention has been recently paid to the development of parent- and child-centered composite DAS for the assessment of health status of children with…
Abstract Number: 073 • 2023 Pediatric Rheumatology Symposium
Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy
Claire Yang¹, Natalie Rosenwasser², Xing Wang², Zheng Xu², Joshua Scheck², Ramesh Iyer³ and Yongdong (Dan) Zhao³, ¹University of Washington School of Medicine, Seattle, WA, ²Seattle Children's Hospital, seattle, WA, ³University of Washington, Seattle, WA
Background/Purpose: Chronic Recurrent Multifocal Osteomyelitis (CRMO) is an autoinflammatory bone disease requiring immunosuppressive therapy in half of patients. Monoclonal Tumor Necrosis Factor inhibitors (TNFi) are…
Abstract Number: 101 • 2023 Pediatric Rheumatology Symposium
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Susan Kim¹, Rebecca Olveda² and Jessica Neely², ¹UCSF Benioff Children's Hospital, San Francisco, CA, ²UCSF, San Francisco, CA
Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…
Abstract Number: 0192 • ACR Convergence 2022
Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
Laura Coates¹, Arthur Kavanaugh², Erin McDearmon-Blondell³, Arthur Mandelin⁴, Tianming Gao⁵ and William Tillett⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²University of California San Diego, La Jolla, CA, ³AbbVie, Inc., Mettawa, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵AbbVie, Inc., North Chicago, IL, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: RAPID3 (Routine Assessment of Patient Index Data 3) is a disease activity index calculated from 3 patient-reported measures: physical function, pain, and patient global…
Abstract Number: 0344 • ACR Convergence 2022
Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie Bartels⁴, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Lupus, the leading cause of chronic kidney disease (CKD) in young women, is treated with Hydroxychloroquine (HCQ) which is primarily excreted by kidneys. Yet…
Abstract Number: 0523 • ACR Convergence 2022
The Development of the Ranked Composite Important Difference in Diffuse Cutaneous Systemic Sclerosis; A Clinical and Patient Meaningful Anchor to the ACR-Composite Response Index in SSc
Lesley-Anne Bissell¹, Daniel Furst², sindhu johnson³, Paul hansen⁴, Esmeralda Recalde⁵, Dinesh Khanna⁶ and Francesco Del Galdo⁷, ¹University of Leeds, Leeds, United Kingdom, ²University of California Los Angeles, Los Angeles, CA, ³Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴University of Otago, Dunedin, New Zealand, ⁵World Scleroderma Foundation, Florence, Italy, ⁶Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: The ACR Composite Response Index in Systemic Sclerosis ( ACR-CRISS) is one of the first composite outcome measures in diffuse cutaneous Systemic sclerosis (dcSSc-…
Abstract Number: 0901 • ACR Convergence 2022
Factors Associated with Household Work Limitations in Mexican Patients with Rheumatoid Arthritis: The Impact of the Disease on Women’s Life
Ana Ortiz-Haro¹, Irazu Contreras-Yáñez¹, Guillermo Guaracha Basañez² and Virginia Pascual Ramos³, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is the most frequent chronic inflammatory arthritis with a clear female preponderance. For various reasons, women spend more time on household…
Abstract Number: 1340 • ACR Convergence 2022
Nutrition-Related Behaviors and Beliefs – A Survey of Rheumatic Disease Patients
Sandy Lee¹, Leanna Wise² and Stavros Savvas³, ¹University of Southern California, Walnut, CA, ²LAC+USC/Keck Medicine of USC, Pasadena, CA, ³Keck Medicine of USC, Glendale, CA
Background/Purpose: Diet and nutrition have long been of interest to both patients and providers in the treatment of chronic disease. The literature is relatively sparse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].